AMSP (Arzneimittelsicherheit in der Psychiatrie) as a model for a pharmacovigilance system for psychiatric inpatient populations by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Annals of General Psychiatry
Open AccessOral presentation
AMSP (Arzneimittelsicherheit in der Psychiatrie) as a model for a 
pharmacovigilance system for psychiatric inpatient populations
Hans-Jórgen Mφller
Address: Psychiatric University Department Munich, Germany
The AMSP-Project (Arzneimittelsicherheit in der Psychi-
atrie) is a prospective multicenter program for continuous
assessment of ADRs of marketed psychotropic drugs in
psychiatric inpatients under naturalistic conditions of
routine clinical treatment. It corresponds to a dynamic
cohort study meaning the cohort - the patient population
of the participating clinics - is changing over time. Cur-
rently 60 hospitals in Germany, Switzerland, Austria, Bel-
gium and Hungary are participating in the AMSP project,
monitoring about 30,000 inpatients per year. Severe ADRs
are detected by active and regular screening of all partici-
pating wards by local drug-monitors. They are docu-
mented and analysed in a standardised manner, to allow
easy data collection and retrieval for more in depth analy-
ses. Causality assessments include time correlations, alter-
native causes, underlying diseases, spontaneous events
and knowledge about the same type of ADR. Each severe
ADR case, and the association between ADR and pharma-
cological treatment, is discussed during pharmacovigi-
lance conferences, held several times per year.
To estimate the incidence of all assessed ADRs all prescrip-
tions of the wards are assessed on two references per year.
Use of psychotropic drugs has been changing drastically
over the years emphasizing the need for continuous ADR
assessment to detect resulting changing ADR pat-
terns.Incidences for severe ADRs of 1.5% about have been
found. The mean hospitalisation length of the surveyed
psychiatric patient population is compared to that of the
serious ADR cases. The length of hospitalisation for seri-
ous ADR cases showed to be more than doubled.
The database exists now for15 years and several studies
have been undertaken using pharmacoepidemiological
tools to assess cause and effect.
Besides being an efficient pharmacovigilance instrument,
the AMSP-Project has turned out to be a valuable quality
assurance instrument in as much as it seems to increase
the awareness of participating physicians and other health
providers of drug safety issues.
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